Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease
Provided By GlobeNewswire
Last update: Aug 21, 2025
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –
Read more at globenewswire.comNASDAQ:STTK (12/10/2025, 10:43:01 AM)
3.125
-0.02 (-0.48%)
Find more stocks in the Stock Screener
STTK Latest News and Analysis
